Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Phase 2 Study of Darbepoetin Alfa Extended Dosing
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 98
- Registration Number
- NCT00527215
Fixed Dose NESP Study in Subjects With CRI
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT00526929
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis-Type PsoriasisPlaque-Type Psoriasis
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00521339
- Locations
- 🇺🇸
Oregon Medical Research Center, P.C., Portland, Oregon, United States
🇺🇸Central Dermatology, Saint Louis, Missouri, United States
🇺🇸Tufts-New England Medical Center Hospitals, Boston, Massachusetts, United States
Denosumab Adherence Preference Satisfaction Study
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00518531
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Phase 3
Completed
- Conditions
- OsteopeniaOsteoporosisLow Bone Mineral Density
- Interventions
- Biological: denosumab
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 311
- Registration Number
- NCT00515463
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Phase 1
Completed
- Conditions
- Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraThrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT00515203
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Phase 2
Completed
- Conditions
- Locally Recurrent and Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 228
- Registration Number
- NCT00511459
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 312
- Registration Number
- NCT00511238
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Northwest Cancer Center, Houston, Texas, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 154
- Registration Number
- NCT00508404
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 213
- Registration Number
- NCT00508625
© Copyright 2025. All Rights Reserved by MedPath